Pharmaceutical depyrogenation equipment market seen reaching $1.36B by 2030

By AI, Created 1:51 PM UTC, May 29, 2026, /AGP/ – The pharmaceutical depyrogenation equipment market is projected to grow from $0.93 billion in 2025 to $1.01 billion in 2026, according to The Business Research Company. The report points to stronger demand for sterile drug manufacturing, injectable medicines, vaccines and biologics as key drivers, with Asia-Pacific expected to post the fastest growth.

Why it matters: - Pharmaceutical depyrogenation equipment is a critical part of sterile drug production because it removes pyrogens, especially bacterial endotoxins, from glassware, containers and other components. - The market’s growth tracks the broader rise in injectable drugs, vaccines and biologics, where contamination control directly affects patient safety and regulatory compliance.

What happened: - The Business Research Company published a 2026 report on the pharmaceutical depyrogenation equipment market with forecasts through 2035. - The market is valued at $0.93 billion in 2025 and is projected to reach $1.01 billion in 2026, which implies 7.6% annual growth. - The market is forecast to reach $1.36 billion by 2030, with a 7.8% CAGR. - The report highlights North America as the largest market in 2025 and Asia-Pacific as the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, market hotspot infographics and technology trend analysis.

The details: - Depyrogenation equipment typically uses high-temperature dry heat to eliminate pyrogens from pharmaceutical components. - The equipment is used to support sterile, pyrogen-free manufacturing for injectable drugs and other sensitive products. - Rising pharmaceutical production, higher injectable drug manufacturing, demand for sterile glassware and containers, and strict endotoxin standards have supported market growth so far. - Growth is also linked to the expansion of vaccine and biologics manufacturing, wider adoption of automated and high-throughput systems, and more IoT-based monitoring and control. - The report says contract manufacturing organizations are becoming a larger part of the demand base as global outsourcing expands. - Key trends during the forecast period include more automated systems, broader use of high-temperature dry heat sterilization, tighter compliance requirements and more real-time process monitoring. - The report describes the equipment as essential for maintaining sterile conditions and protecting patient health. - A free sample of the report is available here. - The full report is available here.

Between the lines: - The fastest demand drivers are not the equipment itself but the production categories that depend on sterile processing, especially injectables, vaccines and biologics. - Automation and digital monitoring appear to be shifting the market from basic batch systems toward higher-throughput, more controlled manufacturing tools. - The regional split suggests mature demand in North America and faster capacity buildout in Asia-Pacific. - The report’s emphasis on regulatory compliance points to a market where technology adoption is shaped as much by quality standards as by production volume.

What’s next: - Demand is likely to keep rising as vaccine, biologics and injectable manufacturing scales further. - Equipment makers will likely focus on automated systems, process monitoring and compliance-focused upgrades. - Growth in contract manufacturing and pharma capacity in Asia-Pacific should add new buyers across the forecast period.

The bottom line: - The market is still relatively small, but sterile manufacturing needs are pushing it into steady, long-term expansion.